Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRUQUITAS: Trifluridine/Tipiracil +/- Fruquintinib for Metastatic Oesogastric Adenocarcinoma
NCT07270991Phase 3Recruiting
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Dec 2025
- Primary completion
- Nov 2030
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 3, randomised trial of fruquintinib in Gastroesophageal junction adenocarcinoma (GEJA) (2 arms), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: Overall Survival at 18 months. Started Dec 2025; status: recruiting.
02
Drugs
fruquintinib
03
Conditions
Gastroesophageal junction adenocarcinoma (GEJA)
Beyond the preview
Go deeper on NCT07270991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07270991.